Stempoint Capital LP Makes New $3.43 Million Investment in Vaxcyte, Inc. $PCVX

Stempoint Capital LP purchased a new stake in Vaxcyte, Inc. (NASDAQ:PCVX) during the first quarter, HoldingsChannel.com reports. The fund purchased 59,061 shares of the company’s stock, valued at approximately $3,432,000.

Other large investors also recently made changes to their positions in the company. NEXTBio Capital Management LP bought a new position in Vaxcyte during the 4th quarter worth about $4,406,000. Norges Bank acquired a new position in shares of Vaxcyte during the fourth quarter worth about $56,703,000. Universal Beteiligungs und Servicegesellschaft mbH grew its holdings in shares of Vaxcyte by 105.3% during the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 70,124 shares of the company’s stock worth $3,236,000 after buying an additional 35,974 shares in the last quarter. Eventide Asset Management LLC raised its position in Vaxcyte by 141.8% in the 4th quarter. Eventide Asset Management LLC now owns 917,115 shares of the company’s stock valued at $42,313,000 after buying an additional 537,785 shares during the last quarter. Finally, Aberdeen Group plc lifted its stake in Vaxcyte by 35.6% in the 4th quarter. Aberdeen Group plc now owns 979,765 shares of the company’s stock valued at $45,206,000 after acquiring an additional 256,972 shares in the last quarter. Institutional investors own 96.78% of the company’s stock.

Insiders Place Their Bets

In other Vaxcyte news, CFO Andrew Guggenhime sold 10,000 shares of the company’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $57.28, for a total value of $572,800.00. Following the transaction, the chief financial officer directly owned 104,395 shares in the company, valued at $5,979,745.60. The trade was a 8.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $49.52, for a total transaction of $111,420.00. Following the completion of the transaction, the chief operating officer directly owned 158,494 shares in the company, valued at $7,848,622.88. The trade was a 1.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 93,646 shares of company stock valued at $5,103,592 over the last ninety days. 3.30% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages have recently commented on PCVX. Wall Street Zen lowered shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research report on Monday, July 6th. Finally, Zacks Research cut Vaxcyte from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $86.00.

Vaxcyte Stock Down 3.0%

PCVX opened at $52.98 on Thursday. Vaxcyte, Inc. has a 12-month low of $29.08 and a 12-month high of $65.00. The business has a 50 day moving average of $52.94 and a 200-day moving average of $54.82. The stock has a market cap of $7.65 billion, a price-to-earnings ratio of -7.70 and a beta of 1.22.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Wednesday, May 6th. The company reported ($2.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same period last year, the business earned ($1.04) earnings per share. As a group, analysts expect that Vaxcyte, Inc. will post -7.91 earnings per share for the current year.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.